Evidence-Based Drug Prescription Algorithm for Gestational Diabetes Mellitus in Indian Hospital Settings

STEP 1: DIAGNOSIS

Use the one-step 75-g OGTT at 24–28 weeks of gestation 1, 2, 3. Diagnose GDM when any one of the following plasma glucose values is met or exceeded:

Fasting: ≥92 mg/dL (5.1 mmol/L)
1-hour: ≥180 mg/dL (10.0 mmol/L)
2-hour: ≥153 mg/dL (8.5 mmol/L)

Indian context: The Diabetes in Pregnancy Study Group India (DIPSI) recommends a simplified single-step procedure using 75-g glucose (non-fasting) with 2-hour plasma glucose >140 mg/dL as diagnostic 4, 5. This approach is endorsed by the Ministry of Health Government of India, WHO, and FIGO for resource-limited settings. However, for optimal maternal-fetal outcomes, use the IADPSG criteria above 1, 2.

Early screening (first prenatal visit): Test women with risk factors using standard non-pregnancy diagnostic criteria (fasting glucose ≥126 mg/dL or A1C ≥6.5%) to identify preexisting diabetes 1. If negative, rescreen at 24–28 weeks.

STEP 2: GLYCEMIC TARGETS FOR MONITORING

All women with GDM require self-monitoring of blood glucose 6. Target values:

Fasting plasma glucose: <95 mg/dL (<5.3 mmol/L)
1-hour postprandial: <140 mg/dL (<7.8 mmol/L) OR
2-hour postprandial: <120 mg/dL (<6.7 mmol/L)

A1C goal in pregnancy: <6% (<42 mmol/mol) if achievable without significant hypoglycemia; may relax to <7% (<53 mmol/mol) if needed 6.

Monitoring frequency: Check fasting glucose daily and postprandial glucose after each meal (3 times daily) initially. Adjust frequency based on control.

STEP 3: LIFESTYLE MODIFICATION (FIRST-LINE FOR ALL)

Initiate medical nutrition therapy and physical activity immediately upon diagnosis 7, 8, 9.

Duration: 1–2 weeks of documented lifestyle intervention before adding pharmacotherapy
Criteria for pharmacotherapy: If ≥20% of glucose values exceed targets after 1–2 weeks of lifestyle modification, or if fasting glucose is persistently ≥95 mg/dL or postprandial values persistently exceed targets 6, 7

Critical pitfall: Do not delay pharmacotherapy beyond 2 weeks if targets are not met. Maternal hyperglycemia directly increases adverse outcomes (macrosomia, preeclampsia, neonatal hypoglycemia) 1.

STEP 4: PHARMACOTHERAPY SELECTION

A. INSULIN (First-Line Pharmacotherapy)

Insulin is the preferred first-line pharmacological treatment according to ACOG 9. It does not cross the placenta and has the most established safety profile 9.

Insulin Initiation:

Starting dose calculation:

Total daily dose (TDD) = 0.7–1.0 units/kg of current body weight in second trimester
TDD = 0.8–1.2 units/kg in third trimester (insulin resistance increases)

Regimen distribution:

50% as basal insulin (NPH or long-acting analogue)
50% as prandial insulin (regular insulin or rapid-acting analogue), divided before meals

Example: 70 kg woman in third trimester:

TDD = 70 kg × 1.0 unit/kg = 70 units/day
Basal: 35 units (NPH at bedtime or split into twice daily)
Prandial: 35 units total → 12 units before breakfast, 12 units before lunch, 11 units before dinner

Insulin Types and Regimens:

Basal insulin:

NPH (Neutral Protamine Hagedorn): Safe, inexpensive, widely available. Give at bedtime or split into twice daily (morning + bedtime) if needed
Insulin detemir or insulin aspart: Analogues with better safety profiles and less hypoglycemia; use if available 8

Prandial insulin:

Regular human insulin: Give 30 minutes before meals
Rapid-acting analogues (lispro, aspart): Give immediately before meals; preferred for better postprandial control and reduced hypoglycemia risk 8

Preferred regimen: Basal-bolus regimen (basal insulin once or twice daily + rapid-acting insulin before each meal) provides optimal control 6.

Insulin Titration:

Adjust every 3–7 days based on glucose patterns:

If fasting glucose >95 mg/dL: Increase bedtime basal insulin by 2–4 units
If postprandial glucose elevated: Increase corresponding prandial insulin by 1–2 units (or 10–20% of current dose)
If hypoglycemia (<60 mg/dL): Decrease corresponding insulin by 2–4 units or 10–20%

Escalation criteria: If glucose targets not met after 1 week of titration, increase insulin doses more aggressively (by 20–30% increments).

B. METFORMIN (Alternative First-Line or Adjunct)

Metformin is an acceptable alternative to insulin according to the Society for Maternal-Fetal Medicine (SMFM), with similar maternal and neonatal outcomes 9, 10. Metformin is superior to glyburide in safety and efficacy 9.

Metformin Initiation:

Starting dose: 500 mg orally once or twice daily with meals 11.

Titration:

Increase by 500 mg weekly based on glucose control and tolerability
Maximum dose: 2500 mg/day (divided into 2–3 doses with meals) 11
Typical effective dose: 1500–2000 mg/day 10

Example regimen:

Week 1: 500 mg once daily with dinner
Week 2: 500 mg twice daily (breakfast + dinner)
Week 3: 1000 mg morning + 500 mg evening
Week 4: 1000 mg twice daily (if needed)

Metformin Efficacy and Limitations:

Success rate: 60–80% of women achieve glycemic control with metformin alone 10
20–40% require supplemental insulin 9, 10
Add insulin if targets not met after 2 weeks at maximum tolerated metformin dose

Advantages:

Oral administration (better patient acceptance)
Reduced maternal weight gain compared to insulin 10
Lower risk of neonatal hypoglycemia 10
Cost-effective

Limitations:

Crosses the placenta (long-term offspring effects under study) 9, 10
Gastrointestinal side effects (nausea, diarrhea) in 20–30% 10
Contraindicated in renal impairment (eGFR <30 mL/min/1.73 m²) 11

Metformin Contraindications:

Renal impairment: eGFR <30 mL/min/1.73 m² (absolute); use caution if eGFR 30–45 mL/min/1.73 m² 11
Hepatic disease
Metabolic acidosis or risk factors (severe infection, hypoxia, dehydration) 11
Alcohol abuse
Hypersensitivity to metformin

Check renal function before initiating metformin and periodically during pregnancy 11.

C. GLYBURIDE (NOT RECOMMENDED)

Glyburide is no longer recommended as first-line therapy 9. It is associated with:

Higher rates of neonatal hypoglycemia
Higher rates of macrosomia
Higher failure rates compared to metformin and insulin 9

Use glyburide only if insulin and metformin are unavailable or refused by the patient.

STEP 5: COMBINATION THERAPY

If metformin monotherapy fails to achieve targets after 2 weeks at maximum tolerated dose, add insulin 9, 10.

Combination regimen:

Continue metformin at current dose
Add basal insulin: Start with 10–20 units NPH at bedtime
Titrate insulin as described above
Add prandial insulin if postprandial values remain elevated despite basal insulin optimization

Rationale: Metformin reduces insulin requirements and maternal weight gain 10.

STEP 6: TRIMESTER-SPECIFIC CONSIDERATIONS

First Trimester:

GDM is typically diagnosed in second trimester; first-trimester hyperglycemia suggests preexisting diabetes 1
Manage as pregestational diabetes with immediate insulin therapy

Second Trimester (14–28 weeks):

Insulin resistance increases progressively
Start with lower insulin doses (0.7–1.0 units/kg)
Metformin initiation is safe

Third Trimester (≥28 weeks):

Insulin resistance peaks
Increase insulin doses by 20–50% to maintain targets
Insulin requirements may increase weekly; titrate aggressively
Fetal surveillance: Begin weekly non-stress tests and biophysical profiles at 32–34 weeks if on medication 7

STEP 7: MATERNAL-FETAL MONITORING

Maternal Monitoring:

Glucose monitoring: Fasting + postprandial (1-hour or 2-hour) daily
A1C: Every 4–6 weeks (target <6% if achievable without hypoglycemia) 6
Blood pressure: Every visit (screen for preeclampsia)
Renal function: If on metformin, check eGFR at baseline and periodically 11
Ketone monitoring: Check urine ketones if fasting glucose >95 mg/dL or if patient is unwell

Fetal Monitoring:

Ultrasound for fetal growth: Every 3–4 weeks starting at 28 weeks (assess for macrosomia, polyhydramnios)
Non-stress test (NST): Weekly starting at 32–34 weeks if on pharmacotherapy 7
Biophysical profile: If NST non-reactive or other concerns
Doppler studies: If fetal growth restriction or hypertension

STEP 8: HYPOGLYCEMIA MANAGEMENT

Hypoglycemia definition: Blood glucose <60 mg/dL 6.

Mild Hypoglycemia (Patient Conscious):

Immediate treatment: 15–20 g fast-acting carbohydrate (3–4 glucose tablets, 120 mL fruit juice, 1 tablespoon honey)
Recheck glucose in 15 minutes
Repeat treatment if glucose still <70 mg/dL
Follow with complex carbohydrate + protein snack once glucose normalizes

Severe Hypoglycemia (Patient Unconscious or Unable to Swallow):

Administer glucagon 1 mg intramuscularly or subcutaneously
Call for emergency assistance
Position patient on left side (prevent aspiration)
IV dextrose 25 g (50 mL of 50% dextrose) if IV access available
Recheck glucose every 15 minutes until >70 mg/dL

Prevention:

Reduce insulin dose by 10–20% if recurrent hypoglycemia
Ensure regular meals and snacks (3 meals + 2–3 snacks daily)
Educate patient on hypoglycemia symptoms (sweating, tremor, confusion, hunger)
Provide glucagon kit to all patients on insulin

STEP 9: INTRAPARTUM MANAGEMENT

Glucose Control During Labor:

Target glucose during labor: 70–110 mg/dL 6.

For women on insulin:

Hold long-acting insulin on morning of delivery
Hold short-acting insulin during active labor
Check glucose every 1–2 hours during labor
IV dextrose 5% at 100–125 mL/hour if glucose <70 mg/dL
IV regular insulin infusion (0.5–1 unit/hour) if glucose >110 mg/dL

For women on metformin:

Hold metformin on day of delivery

Timing of Delivery:

Well-controlled GDM (diet or metformin alone): Await spontaneous labor up to 40 weeks
GDM on insulin or poor control: Consider delivery at 39 weeks (individualize based on control and fetal status) 7
Do not deliver before 39 weeks unless obstetric indication (reduces neonatal respiratory morbidity)

STEP 10: POSTPARTUM MANAGEMENT

Immediate Postpartum (First 24–48 Hours):

Discontinue all diabetes medications immediately after delivery 6, 7.

Insulin requirements drop precipitously after placental delivery
Monitor glucose 4 times daily for first 24–48 hours
Restart medications only if glucose >140 mg/dL fasting or >180 mg/dL postprandial (suggests preexisting diabetes)

Neonatal Monitoring:

Check neonatal glucose at 1,3,6,12, and 24 hours of life (risk of hypoglycemia)
Early and frequent breastfeeding (every 2–3 hours) to prevent neonatal hypoglycemia
Monitor for respiratory distress, hyperbilirubinemia, polycythemia

Postpartum Screening (6–12 Weeks):

All women with GDM require 75-g OGTT at 6–12 weeks postpartum to screen for persistent diabetes 1, 3, 7.

Interpretation:

Fasting glucose ≥126 mg/dL or 2-hour glucose ≥200 mg/dL: Diabetes
Fasting glucose 100–125 mg/dL or 2-hour glucose 140–199 mg/dL: Prediabetes
Normal: Rescreen every 1–3 years lifelong (50% risk of developing type 2 diabetes within 10 years) 3

If prediabetes diagnosed: Initiate lifestyle interventions or metformin for diabetes prevention 12, 13.

STEP 11: SAFETY WARNINGS AND CONTRAINDICATIONS

Insulin:

Risk of hypoglycemia (especially with rapid-acting analogues or aggressive titration)
Weight gain (less than with glyburide)
Injection site reactions (rare)
No absolute contraindications in pregnancy

Metformin:

Crosses placenta: Long-term offspring metabolic effects under investigation 9, 10
Gastrointestinal side effects: Nausea, diarrhea, abdominal discomfort (20–30%) 10
Lactic acidosis risk: Rare but serious; avoid in renal/hepatic impairment, sepsis, hypoxia 11
Vitamin B12 deficiency: With long-term use (monitor if used postpartum)

Absolute contraindications:

eGFR <30 mL/min/1.73 m² 11
Metabolic acidosis
Severe hepatic disease
Acute illness with risk of tissue hypoxia

Relative contraindications:

eGFR 30–45 mL/min/1.73 m² (use caution; not recommended for initiation) 11

Glyburide (If Used):

Crosses placenta (unlike insulin)
Higher neonatal hypoglycemia risk 9
Higher macrosomia risk 9
Contraindicated in renal/hepatic impairment

STEP 12: ALGORITHM SUMMARY (DECISION TREE)

GDM Diagnosed (OGTT at 24–28 weeks)
         ↓
Initiate Lifestyle Modification (Medical Nutrition Therapy + Exercise)
         ↓
Monitor Glucose Daily (Fasting + Postprandial) for 1–2 Weeks
         ↓
Targets Met? (Fasting <95,1-hr <140,2-hr <120 mg/dL)
         ↓
    YES → Continue Lifestyle + Monitor Weekly
         ↓
    NO (≥20% values elevated) → START PHARMACOTHERAPY
         ↓
    ┌────────────────────────────────────┐
    │                                    │
INSULIN (Preferred)              METFORMIN (Alternative)
    │                                    │
Basal-Bolus Regimen              Start 500 mg BID
TDD = 0.7–1.0 units/kg           Titrate to 2000–2500 mg/day
50% Basal + 50% Prandial         over 2–4 weeks
    │                                    │
Titrate Every 3–7 Days           Targets Met After 2 Weeks?
    │                                    │
    │                               YES → Continue
    │                                    │
    │                               NO → ADD INSULIN
    │                                    │
    └────────────────┬───────────────────┘
                     ↓
         Targets Met? (Weekly Assessment)
                     ↓
                 YES → Continue + Monitor
                     ↓
                 NO → Increase Doses Aggressively
                     ↓
         Intrapartum: Hold Medications, Monitor Glucose Q1–2H
                     ↓
         Postpartum: STOP All Medications Immediately
                     ↓
         OGTT at 6–12 Weeks Postpartum (Screen for Persistent Diabetes)

KEY CLINICAL PEARLS

Do not delay pharmacotherapy beyond 2 weeks if lifestyle modification fails—maternal hyperglycemia directly harms the fetus 1.
Insulin is the gold standard with the most safety data; metformin is an acceptable alternative with similar outcomes 9, 10.
Glyburide is inferior to both insulin and metformin—avoid as first-line 9.
Insulin requirements increase throughout pregnancy—titrate aggressively in third trimester (may need 20–50% dose increases) 6.
Metformin fails in 20–40% of women—add insulin promptly if targets not met after 2 weeks at maximum dose 9, 10.
Check renal function before starting metformin and avoid if eGFR <30 mL/min/1.73 m² 11.
Discontinue all diabetes medications immediately postpartum—insulin needs drop precipitously after placental delivery 6, 7.
All women with GDM need lifelong diabetes screening—50% will develop type 2 diabetes within 10 years 3.
Hypoglycemia is the main risk with insulin—educate patients, provide glucagon, and reduce doses if recurrent episodes 6.
Fetal surveillance is mandatory if on pharmacotherapy—weekly NSTs starting at 32–34 weeks 7.

This algorithm prioritizes maternal and fetal safety, evidence-based glycemic targets, and practical implementation in Indian hospital settings. Always individualize care based on patient response, comorbidities, and resource availability. Specialist supervision (endocrinologist, maternal-fetal medicine) is recommended for complex cases.

Have a follow-up question?